Cargando…
P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY
Autores principales: | Habier, Angela, Debes, Anette, Muenster, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430012/ http://dx.doi.org/10.1097/01.HS9.0000972900.20438.84 |
Ejemplares similares
-
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021) -
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012) -
Surveillance study on the tolerability and safety of Flebogamma(®)
DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients
por: Alsina, Laia, et al.
Publicado: (2017) -
Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
por: Ricci, Silvia, et al.
Publicado: (2020) -
Virus safety of intravenous immunoglobulin: Future challenges
por: Boschetti, Nicola, et al.
Publicado: (2005)